Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Androgen blockade · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Androgen blockade for 6 months + Radiotherapy 70 Gy |
| Arm 2 | EXPERIMENTAL | Androgen blockade for 6 months + Radiotherapy 76 Gy |
| Arm 3 | ACTIVE_COMPARATOR | Radiotherapy alone with 76 Gy |
| Name | Type | Description |
|---|---|---|
| Radiotherapy 70 Gy | RADIATION | Radiotherapy to the prostate |
| Radiotherapy 76 Gy | RADIATION | Radiotherapy to the prostate |
| Androgen blockade | DRUG | Duration : 6 months |
Inclusion Criteria: * Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is less than or equal to 6, as well as a prostate-specific antigen (PSA) between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated adenocarcinoma of the prostate,...
Top 20 of 53 competitors
Androgen blockade is used for the treatment of prostate cancer. It is an investigational small molecule therapy being studied in a Phase 3 clinical trial. The therapy is being evaluated in combination with radiation therapy to assess its role in treating prostate cancer.
Androgen blockade is being developed by AstraZeneca PLC, a biopharmaceutical company. The company's stock is traded under the ticker symbol AZN. AstraZeneca is conducting clinical research to evaluate the safety and efficacy of this therapy for prostate cancer.
Androgen blockade is currently in Phase 3 clinical development. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial is active but not recruiting participants, and it is designed to evaluate the therapy's efficacy in prostate cancer.
Androgen blockade is being studied in a Phase 3 clinical trial with the identifier NCT00223145. This trial is titled 'Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone.' The trial is active but not recruiting, with an enrollment of 600 participants in Canada.
Androgen blockade is a form of hormonal therapy used in prostate cancer treatment. In the clinical trial NCT00223145, it is referred to as hormonal treatment. The therapy works by targeting androgen signaling, which is important in prostate cancer progression.